Cyclotriazadisulfonamide

Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP) -dependent way. Cyclotriazadisulfonamide is also a Sec61 translocon inhibitor[1][2][3].

Product Specifications

CAS Number

[182316-44-5]

Product Name Alternative

CADA

UNSPSC

12352005

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cyclotriazadisulfonamide.html

Purity

98.45

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming)

Smiles

O=S(N1CC(CN(S(=O)(C2=CC=C(C)C=C2)=O)CCCN(CC3=CC=CC=C3)CCC1)=C)(C4=CC=C(C)C=C4)=O

Molecular Formula

C31H39N3O4S2

Molecular Weight

581.79

References & Citations

[1]Kurt Vermeire, et al. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res. 2008 May;6 (3) :246-56.|[2]Victor Van Puyenbroeck, et al. Preprotein signature for full susceptibility to the co-translational translocation inhibitor cyclotriazadisulfonamide. Traffic. 2020 Feb;21 (2) :250-264.|[3]Pauwels E, et al. Inhibitors of the Sec61 Complex and Novel High Throughput Screening Strategies to Target the Protein Translocation Pathway. Int J Mol Sci. 2021 Nov 5;22 (21) :12007.